A group of Senate Democrats sent a letter to Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. on Tuesday questioning whether he has divested his financial stake in a lawsuit involving the HPV vaccine Gardasil. The lawmakers are seeking clarification on whether Kennedy adhered to ethics commitments made during his confirmation process regarding his ties to litigation against the pharmaceutical company Merck.
Before his confirmation as HHS Secretary, Kennedy was involved in a lawsuit led by the law firm Wisner Baum. The legal action alleged that Merck’s Gardasil vaccine caused neurological and autoimmune injuries. Merck settled the case for $50 million earlier this year without admitting guilt, maintaining that the vaccine is safe and effective. Gardasil was first approved for use in females in 2006 and for males in 2009.
During his confirmation, Kennedy stated he would divest his interests by assigning them to a non-dependent, adult son. However, Sen. Elizabeth Warren (D-Mass.) stated in the letter that a review of public financial disclosures and ethics documents revealed no amendments or modifications reflecting this change. The senators, including Ron Wyden (D-Oreg.), Richard Blumenthal (Conn.), and Angela Alsobrooks (Md.), requested details on whether the stake was transferred to his son or to Wisner Baum, and what fees Kennedy expects to receive from the $50 million settlement.
The scale of the financial matter involves a $50 million settlement distributed among various plaintiffs and legal counsel. While the specific portion designated for Kennedy has not been publicly reported, the senators noted he previously claimed he was entitled to a share of the fees. For Merck, a major pharmaceutical employer and manufacturer, the outcome of such ethics inquiries can influence market stability and public trust in regulatory neutrality. For families and individuals who use Gardasil, the consistency of federal oversight is a key factor in their healthcare decisions and their confidence in government safety data.
The concrete day-to-day impact for the public centers on the transparency of government ethics. If a Cabinet secretary retains a stake in private litigation against a regulated entity, it sets a precedent for how financial conflicts are managed across all federal departments. The knock-on effects could include changes to how the Senate Finance Committee vets future nominees or how the Office of Government Ethics monitors compliance. What happens next depends on the response from HHS and Wisner Baum; the senators have demanded specific documentation of the transfer, and any further action would likely follow a review of those materials.